Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer
Lantern PharmaLantern Pharma(US:LTRN) Businesswire·2026-06-02 20:13

公司动态 - 公司以8-K表格形式提交了一份演示文稿 [1]

Lantern Pharma Reports HARMONIC™ Data Showing LP-300 Progression-Free Survival Benefit Deepens with Treatment Duration in EGFR Exon 21 L858R Lung Cancer - Reportify